Bayer Aktiengesellschaft

Bayer Cropscience Ag

Horst-Peter Antonicek

J&ouml;rg Baumgarten

Karsten Von Dem Bruch

Udo Stropp

Arnd Voerste

Axel Kretschmer

Jean-Marie-Viktor De Vry

Andreas Stolle

Rudy Schreiber

Ervin Horv&aacute;th

Thomas M&uuml;ller

Gerhard M&uuml;ller

Stephen Lensky

Thomas Jaetsch

Andreas Schoop

Walter Guarnieri

Ulrike Wachendorff-Neumann

Peter Dahmen

Thomas Seitz

Kerstin Ilg

Karl-Heinz Kuck

Uwe Petersen

Herbert Gayer

Ulrich Heinemann

Erwin Bischoff

Hans-Georg Lerchen

Stefan Hillebrand

Stefan Herrmann

Thomas Krahn

Michael Sperzel

Klaus Dieter Bremm

Burkhard Mielke

Ronald Ebbert

Oliver Guth

Wolfgang Springer

Jorg Baumgarten

Helga Rubsamen-Waigmann

Olaf Gebauer

Walter Weichel

Matthias Gehling

Jörg Baumgarten

Maria-Luisa Rodriguez

Norbert Piel

Lothar Biesert

Frank Bohnenstengel

Bambang Wahyu Nugroho

Peter Proksch

Daniel Gondol

Helmuth Sch&uuml;tz

Oliver Gutbrod

Thomas-Peter Hausner

Hary Suhartono

Mark-Michael Struck

Antonius Loebberding

Pyrazolopyrimidines of the formula in whichR, R, R, R, Rand X are as defined in the description,processes for preparing these compounds and their use for controlling unwanted microorganisms.

Pyrazolopyrimidines

The invention relates to cyclopentabenzofuran derivatives, process for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-&#x3ba;B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.

Cyclopentabenzofuran derivatives and their use

The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Substituted &agr;, &bgr;-anellated butyrolactones

The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.

Use of cyclopentabenzofuran-derivatives for combating (NF-&kgr;B)-dependent diseases

The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Substituted &bgr;,&ggr;-anellated lactones

The invention relates to cyclopentabenzofuran derivatives, processes for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-&kgr;B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.

The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.

Substituted bicyclic lactones

The present invention relates to the use of known efomycins and elaiophylins for the treatment of autoimmune disorders, to new natural substances efomycins M and T, and processes for their preparation; in particular to their use as medicaments in psoriasis therapy.

Use of efomycins

The invention relates to cytostatics which, by modification with sugar, are tumor-specific. Suitable spacers ensure serum stability and at the same time an intracellular action.

Sugar-modified cytostatics

The present invention relates to the targeted blocking of the genetic information of the viral messenger ribonucleic acid (mRNA) for virus replication (e.g. of HIV) in transfected, haematopoietic cells with particularly suitable expression systems, which express a complementary 'antisense RNA'.

HIV antisense expression vectors

Growing community of inventors

Bergisch Gladbach, Germany

Horst-Peter Antonicek